News | July 17, 2024
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Shoff brings over 30 years of international experience in in vitro diagnostics, healthcare distribution and veterinary diagnostics
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
This product will be manufactured at Lupin’s Pithampur facility in India
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Subscribe To Our Newsletter & Stay Updated
